AASLD 2016: The Liver Conference – Alan Franciscus
Abstract # 955-Hepatitis C could now be cured for under US $100 per person: analysis of mass generic production of Direct Acting Antivirals—A M Hill et al.
The aim of this study was to calculate the cost of generic drugs to treat hepatitis C. The HCV medications evaluated were sofosbuvir, daclatasvir, ledipasvir and velpatasvir. The cost per pill was combined with formulation (chemical synthesis, raw materials, inactive ingredients). A profit margin of 50% was added.
Conclusion: The 12-week treatment for sofosbuvir is $62; daclatasvir $14; sofosbuvir plus ledipasvir $96; velpatasvir $119-154. The prices include a 50% profit margin for the generic suppliers.
Calculated target prices and current prices for 12-week DAA treatment courses (below):
Target price per 12-week treatment
Current global lowest price per 12-week treatment
Current US price per 12-week treatment
Editorial Comments: It is unlikely that hepatitis C will be eradicated worldwide at least in our lifetime. Access to generic drugs will help, but basic services are lacking in many countries including preventive services that are the key to eradicating HCV. Even in the United States—a resource rich country—we are not providing treatment and little preventive services to the most common group that is affected by hepatitis C – people who inject drugs. We are very far from eradicating hepatitis CShare This Page